Release Date: 28/12/11 08:26 Summary: Substantial shareholder notices received Price Sensitive: No Download Document 1.53MB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%